Przejdź do zawartości
Merck
Wszystkie zdjęcia(2)

Dokumenty

38956

Supelco

Simvastatin

analytical standard

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(2)

About This Item

Wzór empiryczny (zapis Hilla):
C25H38O5
Numer CAS:
79902-63-9
Masa cząsteczkowa:
418.57
Numer MDL:
MFCD00072007
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329755810
NACRES:
NA.24

klasa czystości

analytical standard

Poziom jakości

100

Próba

≥98.0% (HPLC)

aktywność optyczna

[α]/D +275±25°, c = 1 in acetonitrile

okres trwałości

limited shelf life, expiry date on the label

metody

HPLC: suitable
gas chromatography (GC): suitable

zanieczyszczenia

≤0.5% water

mp

127-132 °C (lit.)

Zastosowanie

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

temp. przechowywania

2-8°C

ciąg SMILES

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

Klucz InChI

RYMZZMVNJRMUDD-HGQWONQESA-N

informacje o genach

human ... HMGCR(3156)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Zastosowanie

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Działania biochem./fizjol.

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).
This page may contain text that has been machine translated.

Piktogramy

Health hazard
GHS08

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

H361d

Zwroty wskazujące środki ostrożności

P201 - P202 - P280 - P308 + P313 - P405 - P501

Klasyfikacja zagrożeń

Repr. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number
BCCK8867
BCCG4003
BCCC8162
BCCB9688
BCCB7519

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 8

1 of 8

Lovastatin European Pharmacopoeia (EP) Reference Standard

L0790000

Lovastatin

Simvastatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1438

Simvastatin

Simvastatin European Pharmacopoeia (EP) Reference Standard

S0650000

Simvastatin

Mevinolin from Aspergillus sp. ≥98% (HPLC)

Sigma-Aldrich

M2147

Mevinolin from Aspergillus sp.

Mevastatin ≥98% (HPLC), powder or crystals

Sigma-Aldrich

M2537

Mevastatin

Simvastatin for system suitability CRS European Pharmacopoeia (EP) Reference Standard

Y0002069

Simvastatin for system suitability CRS

Lovastatin United States Pharmacopeia (USP) Reference Standard

USP

1370600

Lovastatin

Simvastatin United States Pharmacopeia (USP) Reference Standard

USP

1612700

Simvastatin

Peter J Kirkpatrick et al.
The Lancet. Neurology, 13(7), 666-675 (2014-05-20)
The benefit of statins in patients with acute aneurysmal subarachnoid haemorrhage is unclear. We aimed to determine whether simvastatin 40 mg could improve the long-term outcome in patients with this disorder. In this international, multicentre, randomised, double-blind trial, we enrolled
Joost Besseling et al.
JAMA, 313(10), 1029-1036 (2015-03-11)
Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In contrast, statins increase the cellular cholesterol uptake and are associated with increased risk for type 2 diabetes mellitus. We hypothesize that
Jennifer G Robinson et al.
JAMA, 311(18), 1870-1882 (2014-05-16)
In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3
A Marot et al.
Acta clinica Belgica, 66(2), 134-136 (2011-06-03)
Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome P-450 (CYP) 3A4 inhibitors. We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone
Laura Marin et al.
Expert opinion on drug delivery, 8(9), 1205-1220 (2011-05-28)
Chronic Obstructive Pulmonary Disease (COPD) is a severe disease that leads to a non-reversible obstruction of the small airways. The prevalence of this disease is rapidly increasing in developed countries, and in 2020 it has been predicted that this disease
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej